Graft versus host disease

This study tests a drug called pacritinib in people with moderate or severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. cGVHD is an immune disorder that can damage organs and cause disability. Participants must be 18 or older and have not responded to …

This early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein …

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This study tests whether adding axatilimab to standard steroid treatment helps people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 240 participants aged 12 and older will receive either axatilimab or a placebo…

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…

This study tests whether adding the drug belumosudil to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancer who have had a stem cell transplant. About 46 participants will receive belumosudil along with their usual GVHD prevention medicin…

This phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…

This study tests whether combining a drug called axatilimab with a blood-filtering procedure (ECP) can help people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 49 participants who have tried at least two prior treatments will …

This early-phase study tests whether fecal microbiota transplantation (FMT) is safe and feasible for children under 22 who have gut problems after a stem cell transplant. Ten participants will receive FMT via colonoscopy or a nasal tube. The main goal is to check for serious side…

This study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is to …

This phase 2 trial tests whether the drug belumosudil can help people who develop bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The study will enroll 45 participants with new or early-stage BOS. Participants will take belumosudil …

This study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in ro…

This study tests a drug called ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGvHD) that did not improve with steroids. cGvHD is a condition where donor immune cells attack the patient's body after a stem cell transplant. The goal i…

This study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD) from worsening in stem cell transplant recipients. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug delays the need for additional…

This study tests the drug belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and whose condition has not improved with at least two prior treatments. The trial has two phases: the first finds th…

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This study tests whether transplanting a patient's own fecal bacteria can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is a serious condition where donor cells attack the patient's body. The trial will enroll 100 bone marrow transplant patient…

This study tests whether fecal microbiota transplantation (FMT) can safely treat gut graft-versus-host disease (GVHD), a serious complication after stem cell transplants. Researchers will track changes in stool frequency and volume in 50 participants aged 10 to 60. The goal is to…

This study tests a drug called axatilimab against the best available treatments for children aged 2 to 18 with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The trial enrolls 60 participants who have already tried at least two other treat…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and abatacept) can prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancers. About 74 adults will take part. The goal is to reduce severe immune react…

This study tests whether adding madecassoside tablets (from the Centella asiatica plant) to standard treatment can help people with a severe form of chronic graft-versus-host disease that causes skin hardening and joint stiffness. About 30 participants aged 14 to 65 will take the…

This phase 3 trial tests whether iguratimod, a drug already used for rheumatoid arthritis, can safely and effectively treat chronic graft-versus-host disease (cGVHD) in people who have had a stem cell transplant. The study will enroll 20 adults who have persistent cGVHD despite p…

This study tests whether switching to the drug ruxolitinib after a stem cell transplant can better prevent chronic graft-versus-host disease (GVHD) compared to standard treatment. About 40 adults with blood cancers who are in remission will receive either a medium dose of cycloph…

This study tests whether fecal microbiota transplantation (FMT) can help people with severe gut graft-versus-host disease (GvHD) that doesn't respond to steroids. GvHD is a common and dangerous complication after stem cell transplants, where donor cells attack the patient's body.…

This study compares two drug combinations to prevent graft-versus-host disease (GVHD) in people aged 65 and older with certain blood cancers who receive a stem cell transplant. Participants will receive either cyclophosphamide, sirolimus, and MMF or cyclophosphamide, sirolimus, a…

This phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study tests whether giving more doses of the drug abatacept over a longer period can better prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body. About 160 people receiving stem cell transplants from partially ma…

This study tests whether moxibustion, a traditional Chinese medicine technique that involves burning dried mugwort near the skin, can help people with a severe complication of stem cell transplants called graft-versus-host disease (GVHD) that does not respond to steroids. The tri…

This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…

This early study tests whether adding special cells from donated umbilical cord blood (called mesenchymal stromal cells) to the drug ruxolitinib can help control severe graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a serious complication where donor…

This phase 3 trial tests two drugs, Thymoglobulin and Grafalon, to see which one better prevents graft-versus-host disease (GVHD) in patients aged 50-70 with acute myeloid leukemia or myelodysplastic syndrome. All participants receive a stem cell transplant from a matched unrelat…

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This study tests a combination of two drugs, belumosudil and rituximab, as the first treatment for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The goal is to see if this approach can control the disease and reduce the need f…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…

This early-phase trial tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The study will enroll 36 participants to check safety and see if the treatment can reduce symptoms. It's a first s…

This study tests a device that removes specific immune cells from donated stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, where donor cells attack the patient's body. Up to 90 children and young adults (ages 0-30) will receive these treat…

This study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two d…

This phase 2 trial is testing whether adding the drug ruxolitinib to standard steroid treatment can better control severe acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. The study will enroll 54 people who develop severe GVHD within 100…

This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 41 adults and give the…

This study tests a new treatment made from special stem cells (iMSC) for people with a serious complication after bone marrow transplant called graft-versus-host disease that does not respond to steroids. The treatment aims to control the disease by calming the immune system. Abo…

This study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) after a donor stem cell transplant, a condition called chronic graft-versus-host disease. The drug aims to block immune signals that cause inflammation and scarring. About 50 adults…

This early-phase trial tests whether giving patients extra gamma delta T-cells—a type of immune cell that can kill cancer—after a half-matched bone marrow transplant can improve outcomes. The study includes up to 38 adults with leukemia or myelodysplastic syndromes. The goal is t…

This study tests a drug called ruxolitinib for treating acute graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body after a bone marrow transplant. About 98 adults with moderate to severe GVHD will receive either ruxolitinib alone or wi…

This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after stem cell transplants from unrelated or half-matched donors. About 316 participants will receive either a reduced dose (35 mg/kg) or the standard dose (50 mg/kg),…

This early-phase trial is testing an experimental drug called AC-003 in 24 adults who have acute graft-versus-host disease (aGVHD) after a stem cell transplant and whose condition has not improved with steroids. The study aims to see if the drug is safe and tolerable, and to get …

This early-stage study tests whether giving patients a fecal transplant (donated stool) along with extra dietary fiber can help treat gut graft versus host disease, a serious complication after a stem cell transplant. About 72 adults who had a stem cell transplant in the past yea…

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This early-phase study tests whether adding a drug made from urine (uhCG/EGF) to standard therapy can safely prevent graft-versus-host disease (GVHD) in stem cell transplant patients with partially matched donors. About 18 adults with blood cancers who lack a fully matched donor …

This study is testing whether crushing belumosudil tablets and mixing them with water changes how the drug is absorbed in people with chronic graft-versus-host disease (cGVHD). Only 8 participants who have had a stem cell transplant will take the drug both ways and have their blo…

This study tests a drug called axatilimab in 30 Chinese patients with chronic graft-versus-host disease (cGVHD) that has come back or not improved after standard treatment. cGVHD is a complication of bone marrow or stem cell transplants where donor cells attack the patient's body…

This study tests two different pre-transplant conditioning plans combined with a single drug combination (cyclophosphamide and methotrexate) to prevent graft-versus-host disease (GVHD) in blood cancer patients receiving a stem cell transplant from a matched donor. About 82 adults…

This study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that h…

This early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells at…

This study tests whether adding ruxolitinib to standard steroids works better than steroids alone for grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplant. About 168 adults who have had a first stem cell transplant for blood cancer and…

This early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have mo…

This phase 3 trial is testing whether changing the timing of stem cell infusion after a single umbilical cord blood transplant can lower the risk of severe acute graft-versus-host disease (aGVHD) in people with blood cancers. The study will enroll 134 participants who are in remi…

This study tests a drug called gecacitinib (jaktinib) combined with steroids as a first treatment for acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. About 35 adults who have had a stem cell transplant and develop moderate to severe GVH…

This study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who have not improved after at least two prior treatments. About 48 participants will take vimseltinib daily for up to two years. The g…

This study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard high dose of a drug (cyclophosphamide) with a lower dose, both combined with another drug (sirolimus), to prevent graft-versus-host disease (GVHD). The goal is to…

This study tests a new drug, rovadicitinib, for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The goal is to see if rovadicitinib improves symptoms better than sta…

This study tests whether putting healthy donor stool into the gut can help people with severe gut inflammation after a stem cell transplant. The condition, called gastrointestinal graft-versus-host disease, is hard to treat and often deadly. Fifteen patients will receive the stoo…

This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…

This study tests a drug called RLS-0071 in 66 hospitalized patients who have severe graft-versus-host disease (GVHD) after a stem cell transplant and did not improve with steroids. The drug is given for 7 to 14 days to see if it is safe and helps control the immune reaction. The …

This study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…

This phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…

This program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…

This study tests whether adding the drug ruxolitinib to the usual anti-rejection medicines (tacrolimus and methotrexate) can prevent graft-versus-host disease (GVHD) in children and young adults getting a stem cell transplant for leukemia or myelodysplastic syndrome. GVHD happens…

This early-phase study tests a new stem cell transplant method for people with aggressive or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially engineered donor cells to reduce the risk of graft-versus-host disease, potentia…

This study offers a special way to prepare donor stem cells for children and teens under 22 who need a transplant but lack a perfectly matched sibling donor. The method uses the CliniMACS® system to remove certain immune cells, which may help reduce the risk of graft-versus-host …

This expanded access program makes an investigational eye drop called d-MAPPS available to adults with chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell or bone marrow transplant. The treatment is a protein-based soluti…

This program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics commi…

This phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …

This phase 2 trial tests a two-step dosing schedule of anti-thymocyte globulin (ATG) combined with standard drugs (tacrolimus and mini methotrexate) to prevent severe graft-versus-host disease (GVHD) in 56 adults with blood cancers like acute leukemia. Participants receive ATG on…

This early-phase trial tests whether infusing specially prepared donor immune cells (Treg cells) along with low-dose interleukin-2 can safely treat refractory chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. The study will enroll 18 a…

This study tests whether adding etanercept to the standard drug ruxolitinib can better control severe graft-versus-host disease (GVHD) in people who have had a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body, and current treatments often fail…

This study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This study tests a personalized approach to stopping the drug Letermovir, which prevents a common virus called CMV after a stem cell transplant. Instead of giving the drug for a fixed 100 days, doctors will use a blood test to see when a patient's own immune system has recovered …

This study tests whether a dietary supplement called galacto-oligosaccharide (GOS) can prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant. GVHD is a serious complication where donor cells attack the patient's body. The supplement aims to cha…

This early-stage trial tests whether the drug ruxolitinib can prevent chronic graft-versus-host disease (cGVHD) in 42 adults who had a stem cell transplant for blood cancer. Doctors use a blood test to find patients at high risk for cGVHD and then give them ruxolitinib to block t…

This early-phase trial tests whether injecting mesenchymal stromal cells (MSCs) into the salivary glands is safe and can ease dry mouth in people with graft-versus-host disease or Sjogren's disease. Up to 36 adults will receive one injection and be monitored for pain and side eff…

This phase 2 trial tests whether photobiomodulation (PBM) — a type of light therapy — can safely treat oral chronic graft-versus-host disease (GVHD), a painful mouth condition that can occur after a stem cell transplant. About 44 participants who have not responded to at least on…

This study is testing a smartphone app that provides nursing, exercise, and nutrition support to people recovering from allogeneic bone marrow transplant. The goal is to learn what kind of help patients find most useful and when they need it. Researchers will interview 45 partici…

This study looks at whether a sleep education program can improve sleep and daily activity for adults getting a bone marrow transplant. Sixty participants will wear a device to track their sleep and movement. The goal is to see if better sleep helps them feel better during recove…

This study is testing a new digital application called SHIFT to see if it can improve sexual health, quality of life, and reduce distress in people who have had a stem cell or bone marrow transplant. The trial will enroll 300 adult survivors who are at least three months post-tra…

This study looks at whether a home-based aerobic and resistance exercise program is feasible for adults with graft-versus-host disease (GVHD) after a stem cell transplant. Participants will either do aerobic and resistance exercises or simple stretching. The goal is to see if exe…

This study tests a group-based telehealth program called HORIZONS for adults living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The program includes 8 sessions led by a therapist to help with self-management and quality of life. Researchers will c…

This study tests an experimental eye drop (rhPRG4) to see if it safely eases dry eye symptoms in people with ocular graft-versus-host disease (oGVHD), a complication after bone marrow transplant. About 15 adults with moderate to severe dry eye will receive both the active drop an…

This pilot study tests whether a non-invasive electrostimulation device can relieve symptoms of chronic ocular graft-versus-host disease, a painful eye condition that can occur after a stem cell transplant. Fifteen participants will receive either real or sham stimulation on thei…

This study tests whether a virtual exercise program can help children and young adults (ages 8-23) recover physical function and quality of life after a stem cell transplant. Participants will have twice-weekly, 30-minute online sessions with a physical therapist for 12 weeks. Th…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study is observing up to 3,500 people with immune system problems, including rare genetic conditions like chronic granulomatous disease and severe combined immunodeficiency. Researchers will track how these diseases change over time through blood tests, imaging, and checkups…

This study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study collects blood stem cells from healthy volunteers after they receive a growth factor injection. Researchers aim to develop better methods to remove the white blood cells that cause graft-versus-host disease, a serious complication of bone marrow transplants. Up to 500 …

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This pilot study is testing a new imaging agent called [18F]4FN in PET/CT scans for people with chronic graft-versus-host disease (GVHD) affecting their joints. The goal is to see if the agent is safe and can help doctors see joint problems more clearly. Sixteen adults with chron…

This study enrolls 300 adults with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Researchers will collect blood samples and medical data before and after treatment to look for changes that might predict how well a patient responds. The goal is to…

This study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…

This study is testing whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will take blood samples from 100 adult patients 28 days after transplant to see if these markers can spot early si…

This study follows 500 adults who received a stem cell transplant at least 10 years ago to see if iron buildup in the body raises the risk of liver problems. Researchers will use blood tests and a special liver scan (FibroScan) to check for damage. The goal is to understand wheth…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study follows 1,500 adults who recently had a stem cell transplant and are at risk for chronic Graft-Versus-Host Disease (cGVHD), a condition where donor cells attack the recipient's body. Researchers will collect data on how often cGVHD occurs, how severe it is, and what he…

This study will follow 100 women who have had a stem cell transplant to better understand a condition called vulvovaginal chronic graft-versus-host disease (cGVHD). Researchers want to learn how common it is, what symptoms look like, and how it affects sexual health. The goal is …

This observational study follows 40 women undergoing stem cell transplants to track changes in their vaginal microbiome (the collection of bacteria and fungi) and see how it relates to vulvovaginal graft-versus-host disease (GVHD), a painful complication. Participants complete sy…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study collects eye fluid, cells, and blood samples from 150 adult cancer patients who have dry eye disease after a stem cell transplant (graft-versus-host disease). Researchers will analyze these samples to find risk factors, markers, and possible treatment targets. The goal…

This study looks at 60 people getting a stem cell transplant to see if their autonomic nervous system (which controls things like heart rate and sweating) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have simple nerve tests be…

This study looks at why some people who have had a stem cell transplant feel very tired and have trouble thinking clearly. Researchers will use brain scans and spinal fluid tests to see if inflammation in the brain is the cause. The goal is to better understand these problems, no…

This study looks at how depression and other mental health issues impact symptom severity and quality of life in people with graft-versus-host disease (GvHD). Researchers will follow 200 adults with GvHD, using questionnaires to measure psychiatric status and symptoms. The goal i…

This study is looking at whether certain carbohydrates in food, called FODMAPs, are related to graft-versus-host disease (GVHD) in people who have had a bone marrow transplant. GVHD is a common complication where donor cells attack the patient's body. Researchers will track 100 t…

This study explores whether nerve damage in the cornea causes stubborn dry eye in people with ocular graft-versus-host disease (GVHD), a complication of stem cell transplants. Researchers will measure corneal sensation in 30 GVHD patients and compare it to healthy controls. The g…

This study looks at whether a special CT scan analysis called parametric response mapping (PRM) can detect early signs of chronic lung disease in people who have had a stem cell transplant. Researchers will follow 375 patients for one year to see if PRM patterns predict lung func…